2006
DOI: 10.1056/nejmoa052664
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: This vaccine was efficacious in preventing rotavirus gastroenteritis, decreasing severe disease and health care contacts. The risk of intussusception was similar in vaccine and placebo recipients. (ClinicalTrials.gov number, NCT00090233.)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

34
1,243
2
51

Year Published

2009
2009
2012
2012

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 1,666 publications
(1,330 citation statements)
references
References 31 publications
34
1,243
2
51
Order By: Relevance
“…During the study until the end of the 2003-2004 winter season the G1;P [8] genotype was widespread while G9:P [8] remained rare. A majority of severe rotavirus gastroenteritis requiring hospitalization may be prevented by the widespread use of rotavirus vaccines [52][53][54]. Noroviruses are the second leading causative agent of gastroenteritis in hospitalized young children and such infections are less severe than those caused by rotavirus.…”
Section: Discussionmentioning
confidence: 99%
“…During the study until the end of the 2003-2004 winter season the G1;P [8] genotype was widespread while G9:P [8] remained rare. A majority of severe rotavirus gastroenteritis requiring hospitalization may be prevented by the widespread use of rotavirus vaccines [52][53][54]. Noroviruses are the second leading causative agent of gastroenteritis in hospitalized young children and such infections are less severe than those caused by rotavirus.…”
Section: Discussionmentioning
confidence: 99%
“…Two of the largest clinical trials in history showed that these vaccines are safe and highly effective for preventing life-threatening dehydrating rotavirus diarrhea, providing either serotype-specific or crossreactive protective immune responses [24,25].…”
Section: Introductionmentioning
confidence: 99%
“…Some preliminary data are available from the U.S., where a live, oral pentavalent rotavirus vaccine (RV5) was introduced in 2006: Vaccine coverage has been estimated at 58% for children aged 3 months (1 dose [8]. The pentavalent vaccine RotaTeq has been estimated to have an efficacy over the first season post-inoculation of 98% against severe forms of rotavirus gastroenteritis [40]. For another vaccine, Rotarix, which was the first approved for use in Europe, approximately 96% of severe infections were prevented in the first year (information from the Rotarix drug label).…”
Section: Vaccinationmentioning
confidence: 99%
“…Many studies have already dealt with the need for safe and effective vaccines to reduce morbidity and mortality caused by rotavirus gastroenteritis in children [3,31,40]. But few studies have focused specifically on other simple preventive measures which could be applied to control nosocomial epidemic risk for pediatric rotavirus outbreaks, like hand washing or disinfection, although their effectiveness has been proven [18].…”
Section: Introductionmentioning
confidence: 99%